Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2913MR)

This product GTTS-WQ2913MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2913MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13235MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ15362MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ3752MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ14990MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ9290MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ12764MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ7285MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ12088MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-03087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW